Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIELLYN vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females aged ≥15 years who have achieved menarche and are not pregnant,Treatment of heavy menstrual bleeding in women without organic pathology who choose oral contraception
Prevention of pregnancy (FDA-approved)
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized via CYP3A4; norethindrone is metabolized primarily via reduction and conjugation, with CYP3A4 involvement.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
97-99% bound primarily to albumin and alpha-1-acid glycoprotein
~99% bound to serum albumin and sex hormone-binding globulin.
4-6 L/kg; extensive tissue distribution, crosses placenta and enters breast milk
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 90-100%, minimal first-pass effect
Oral: ~70% due to first-pass metabolism.
No dose adjustment required. Contraindicated in severe renal impairment or acute renal failure due to potential for fluid retention and hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C hepatic impairment. Use with caution in Child-Pugh class A (mild impairment) with monitoring.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarcheal adolescents, same dosing as adults: 1 tablet orally daily.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific dose adjustment; consider thromboembolic risk and comorbidities.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders, including venous thromboembolism and arterial thrombosis,Risk of myocardial infarction and stroke, especially in smokers and women with hypertension or other cardiovascular risk factors,Hepatic neoplasia (benign and malignant) reported,Gallbladder disease,Carbohydrate and lipid metabolism alterations,Elevated blood pressure,Headache including migraine,Irregular bleeding and amenorrhea,Depression,Carcinoma of the breast and reproductive organs (no conclusive evidence),Decreased effectiveness with concurrent medications like rifampin, anticonvulsants
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Known or suspected breast carcinoma,Hepatic tumors (benign or malignant) or acute liver disease,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Smoking in women over 35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. High-fat meals may slightly reduce absorption but not clinically significant.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Ethinyl estradiol and norethindrone are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects. Second/third trimester: Exposure may increase risk of neonatal withdrawal, jaundice, and fluid retention.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk. M/P ratio not established. May reduce milk production and quality. Use caution, especially in the early postpartum period. Avoid if alternative contraception available.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustment rationale. No pharmacokinetic data supporting use in pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
BRIELLYN is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Advise patients to take at the same time daily to maintain consistent hormone levels. Missed doses increase risk of breakthrough bleeding and pregnancy. Counsel on potential decreased efficacy with certain medications (e.g., rifampin, anticonvulsants). Monitor blood pressure at baseline and follow-up due to estrogenic effects. Discontinue if migraine with aura or unexplained vision changes occur.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, even if you do not have sex.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Use a backup barrier method (e.g., condoms) for the first 7 days of starting BRIELLYN.,Report severe headaches, vision changes, leg pain, or chest pain immediately.,Do not smoke while taking BRIELLYN, especially if over 35, due to increased risk of blood clots.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIELLYN vs AFIRMELLE, answered by our medical review team.
BRIELLYN is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIELLYN and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIELLYN is: BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIELLYN and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIELLYN is classified as Category C. First trimester: Ethinyl estradiol and norethindrone are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects. Second/third trimester: . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.